NAPRELAN

Compare NAPRELAN  to:
Compare
Compare

Generic Name for NAPRELAN

Naproxen (as sodium) 375mg, 500mg, 750mg; controlled rel tabs.

Legal Classification:

Rx

Pharmacological Class for NAPRELAN

NSAID (arylacetic acid deriv.).

Manufacturer of NAPRELAN

Victory Pharma

Indications for NAPRELAN

Rheumatoid arthritis. Osteoarthritis. Ankylosing spondylitis. Acute gout. Tendinitis. Bursitis.

Adult dose for NAPRELAN

Rheumatoid arthritis, osteoarthritis, or ankylosing spondylitis: 750mg–1g once daily; max 1.5g once daily. Acute tendonitis or bursitis: 1g once daily, or 1.5g once daily for a limited period; max 1g/day thereafter. Gout: 1–1.5g once daily for 1 day then 1g once daily until attack subsides.

Children's dosing for NAPRELAN

Not recommended.

Contraindications for NAPRELAN

Aspirin allergy. 3rd trimester pregnancy. Coronary artery bypass graft surgery.

Precautions for NAPRELAN

Advanced renal disease: not recommended. Active peptic ulcer. History of GI disease. Impaired renal or hepatic function. Heart failure. Edema. Hypertension. Pre-existing asthma. Bleeding disorders. Monitor blood, ocular, and liver function in chronic use. Discontinue if liver dysfunction occurs. Elderly. Debilitated. Pregnancy (Cat.C). Nursing mothers: not recommended.

Interactions for NAPRELAN

Avoid aspirin. Serum levels increased by probenecid. May potentiate protein-bound drugs (eg, phenytoin, sulfonylureas, sulfonamides). Monitor oral anticoagulants. May antagonize diuretics, antihypertensives. Increased renal toxicity with ACE inhibitors. Methotrexate excretion reduced. Increases lithium levels. Increased risk of GI bleed with alcohol.

Adverse Reactions for NAPRELAN

GI upset, bleeding, or ulceration; headache, flu syndrome, constipation, abdominal pain, dizziness, paresthesias, insomnia, rash (discontinue if occurs), edema, hyperglycemia, arthralgia, myalgia, renal dysfunction, blood dyscrasias, others. See literature re: risk of cardiovascular events.

How is NAPRELAN supplied?

Tabs 375mg—100
500mg—75
750mg—30
Dose card (10-day therapy)—20 (750mg x 6 tabs + 500mg x 14 tabs)

Related Disease:

Ankylosing spondylitis
Arthritis~NSAIDs
Rheumatoid arthritis

Related Resources

Xiaflex available for Dupuytren's contracture

March 08, 2010

BioSpecifics Technologies and Auxilium Pharmaceuticals announced the availability of Xiaflex (collagenase clostridium histolyticum) for the treatment of adult Dupuytren's contracture patients with a palpable cord.

Xiaflex approved for Dupuytren's contracture

February 03, 2010

Auxilium Pharmaceuticals announced the approval of Xiaflex (collagenase clostridium histolyticum) for the treatment of adult Dupuytren's contracture patients with a palpable cord.

Exel/Exelint infusion set needles recalled

January 26, 2010

FDA notified healthcare professionals of a Class I recall of Exel/Exelint Huber needles, Exel/Exelint Huber Infusion Sets, and Exel/Exelint "Securetouch+" Safety Huber Infusion Sets due to 'coring,' the cutting or dislodging of silicone cores or slivers from the ports into which they are inserted).

Phase 2 study of SBI-087 for treatment of rheumatoid arthritis (RA)

January 11, 2010

Trubion Pharmaceuticals announced the initiation of a Phase 2 trial of SBI-087 for the treatment of rheumatoid arthritis (RA).

Actemra approved for moderately to severely active rheumatoid arthritis

January 11, 2010

The FDA has approved Actemra (tocilizumab, from Roche) for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more tumor necrosis factor (TNF) antagonist therapies.